Biogen said it is investigating the death of a 75-year-old who had taken the company’s new Alzheimer’s drug Aduhelm. The patient was hospitalized and diagnosed with swelling in the brain before dying.
Biogen Inc.
said it is investigating the recent death of a 75-year-old patient who had taken the company’sAfter taking Aduhelm, the patient was hospitalized and diagnosed with swelling in the brain before dying. It isn’t known yet whether the brain swelling was related to Aduhelm, Biogen said Tuesday.
Wir haben diese Nachrichten zusammengefasst, damit Sie sie schnell lesen können. Wenn Sie sich für die Nachrichten interessieren, können Sie den vollständigen Text hier lesen. Weiterlesen: